Form 4: BiomX Inc. (PHGE) Deerfield Entities Acquire Warrants Following Merger Approval
SEC Form 4 Filing
Deerfield entities, including funds and management companies, acquired warrants to purchase BiomX Inc. common stock following stockholder approval related to the Adaptive Phage Therapeutics, Inc. merger.
Summary
- This Form 4 filing reports changes in beneficial ownership of BiomX Inc. (PHGE) securities by James E. Flynn and related Deerfield entities.
- The reported transactions are related to warrants acquired as part of the merger with Adaptive Phage Therapeutics, Inc. (APT).
- The warrants became exercisable on July 9, 2024, following stockholder approval.
- Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. each acquired warrants to purchase 722,175 shares of common stock at an exercise price of $5.
- Additionally, each fund acquired warrants to purchase 20,175,000 shares of common stock at an exercise price of $0.2311.
- The warrants were issued on March 15, 2024, but were not exercisable until stockholder approval was obtained on July 9, 2024.
- The reporting persons disclaim beneficial ownership of the securities except to the extent of their indirect pecuniary interest.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The acquisition of warrants by a reputable firm like Deerfield suggests confidence in the company's future, but it's a standard transaction related to a prior merger agreement.
Positives
- The acquisition of warrants by Deerfield entities signals continued investment and confidence in BiomX Inc. following the merger with Adaptive Phage Therapeutics, Inc.
- The warrants becoming exercisable after stockholder approval removes a prior condition and allows for potential future equity conversion.
Future Outlook
The document does not contain specific forward-looking statements beyond the potential exercise of warrants.
Industry Context
This announcement reflects ongoing investment activity in the biotechnology sector, particularly related to companies involved in mergers and acquisitions. Institutional investors like Deerfield often participate in private placements and warrant offerings to support the growth and development of biotech companies.
Comparison to Industry Standards
- Deerfield Management is a well-known healthcare-focused investment firm, and their investment in BiomX is consistent with their strategy of supporting innovative companies in the biotechnology space.
- Warrant offerings are a common financing tool in the biotech industry, allowing investors to participate in potential future upside while providing companies with capital.
- The exercise prices of the warrants are typical for early-stage biotech companies, reflecting the inherent risks and potential rewards of the sector.
Stakeholder Impact
- The acquisition of warrants could potentially benefit shareholders if the warrants are exercised and the company's stock price increases.
- The investment by Deerfield may provide BiomX with additional financial flexibility to pursue its research and development programs.
Key Dates
| Date | Description |
|---|---|
| 2024/03/06 | Date of the Agreement and Plan of Merger among BiomX Inc., BTX Merger Sub I, Inc., BTX Merger Sub II, LLC and Adaptive Phage Therapeutics, Inc. (APT). |
| 2024/03/15 | Date the Merger Warrants and Private Placement Warrants were originally issued. |
| 2024/03/18 | Date a Form 3 with regard to BiomX Inc. was filed with the Securities and Exchange Commission by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn. |
| 2024/07/09 | Date of earliest transaction and date stockholder approval was obtained, making the warrants exercisable. |
| 2024/07/11 | Date of the signature of the reporting person. |
| 2026/07/09 | Expiration date of warrants to purchase 20,175,000 shares of common stock at an exercise price of $0.2311. |
| 2027/01/28 | Expiration date of warrants to purchase 722,175 shares of common stock at an exercise price of $5. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.